S&P 500   3,632.64 (+1.54%)
DOW   30,072.10 (+1.62%)
QQQ   293.69 (+1.14%)
AAPL   114.91 (+0.93%)
MSFT   213.61 (+1.67%)
FB   274.29 (+2.18%)
GOOGL   1,754.55 (+1.56%)
AMZN   3,123.92 (+0.82%)
TSLA   546.78 (+4.78%)
NVDA   518.71 (-1.31%)
BABA   277.33 (+2.67%)
CGC   26.95 (+9.02%)
GE   10.56 (+4.87%)
MU   63.02 (-1.81%)
AMD   84.64 (-0.79%)
T   29.26 (+2.24%)
NIO   52.99 (-4.32%)
F   9.43 (+6.43%)
ACB   9.08 (+26.46%)
NFLX   482.24 (+1.18%)
GILD   60.89 (+1.67%)
BA   220.33 (+4.16%)
DIS   151.58 (+3.84%)
S&P 500   3,632.64 (+1.54%)
DOW   30,072.10 (+1.62%)
QQQ   293.69 (+1.14%)
AAPL   114.91 (+0.93%)
MSFT   213.61 (+1.67%)
FB   274.29 (+2.18%)
GOOGL   1,754.55 (+1.56%)
AMZN   3,123.92 (+0.82%)
TSLA   546.78 (+4.78%)
NVDA   518.71 (-1.31%)
BABA   277.33 (+2.67%)
CGC   26.95 (+9.02%)
GE   10.56 (+4.87%)
MU   63.02 (-1.81%)
AMD   84.64 (-0.79%)
T   29.26 (+2.24%)
NIO   52.99 (-4.32%)
F   9.43 (+6.43%)
ACB   9.08 (+26.46%)
NFLX   482.24 (+1.18%)
GILD   60.89 (+1.67%)
BA   220.33 (+4.16%)
DIS   151.58 (+3.84%)
S&P 500   3,632.64 (+1.54%)
DOW   30,072.10 (+1.62%)
QQQ   293.69 (+1.14%)
AAPL   114.91 (+0.93%)
MSFT   213.61 (+1.67%)
FB   274.29 (+2.18%)
GOOGL   1,754.55 (+1.56%)
AMZN   3,123.92 (+0.82%)
TSLA   546.78 (+4.78%)
NVDA   518.71 (-1.31%)
BABA   277.33 (+2.67%)
CGC   26.95 (+9.02%)
GE   10.56 (+4.87%)
MU   63.02 (-1.81%)
AMD   84.64 (-0.79%)
T   29.26 (+2.24%)
NIO   52.99 (-4.32%)
F   9.43 (+6.43%)
ACB   9.08 (+26.46%)
NFLX   482.24 (+1.18%)
GILD   60.89 (+1.67%)
BA   220.33 (+4.16%)
DIS   151.58 (+3.84%)
S&P 500   3,632.64 (+1.54%)
DOW   30,072.10 (+1.62%)
QQQ   293.69 (+1.14%)
AAPL   114.91 (+0.93%)
MSFT   213.61 (+1.67%)
FB   274.29 (+2.18%)
GOOGL   1,754.55 (+1.56%)
AMZN   3,123.92 (+0.82%)
TSLA   546.78 (+4.78%)
NVDA   518.71 (-1.31%)
BABA   277.33 (+2.67%)
CGC   26.95 (+9.02%)
GE   10.56 (+4.87%)
MU   63.02 (-1.81%)
AMD   84.64 (-0.79%)
T   29.26 (+2.24%)
NIO   52.99 (-4.32%)
F   9.43 (+6.43%)
ACB   9.08 (+26.46%)
NFLX   482.24 (+1.18%)
GILD   60.89 (+1.67%)
BA   220.33 (+4.16%)
DIS   151.58 (+3.84%)
Log in
OTCMKTS:USRM

U.S. Stem Cell Stock Forecast, Price & News

$0.0066
0.00 (0.00 %)
(As of 11/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$0.01
Now: $0.01
$0.01
50-Day Range
$0.01
MA: $0.01
$0.01
52-Week Range
$0.00
Now: $0.01
$0.02
Volume829,066 shs
Average Volume983,247 shs
Market Capitalization$2.87 million
P/E RatioN/A
Dividend YieldN/A
Beta2.7
U.S. Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States and internationally. Its lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. The company's product development pipeline includes MyoCell SDF-1, an autologous muscle-derived cellular therapy for improving cardiac function in chronic heart failure patients. It is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, the company provides physician and patient based regenerative medicine/cell therapy training, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well operates a cell therapy clinic. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was founded in 1999 and is based in Sunrise, Florida.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.56 out of 5 stars


Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:USRM
Previous SymbolNASDAQ:BHRT
CUSIPN/A
CIKN/A
Phone954-835-1500
Employees10

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.70 million
Book Value($0.02) per share

Profitability

Miscellaneous

Market Cap$2.87 million
Next Earnings Date11/25/2020 (Estimated)
OptionableNot Optionable
$0.0066
0.00 (0.00 %)
(As of 11/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive USRM News and Ratings via Email

Sign-up to receive the latest news and ratings for USRM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











U.S. Stem Cell (OTCMKTS:USRM) Frequently Asked Questions

How has U.S. Stem Cell's stock price been impacted by COVID-19 (Coronavirus)?

U.S. Stem Cell's stock was trading at $0.0061 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, USRM shares have increased by 8.2% and is now trading at $0.0066.
View which stocks have been most impacted by COVID-19
.

What stocks does MarketBeat like better than U.S. Stem Cell?

Wall Street analysts have given U.S. Stem Cell a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but U.S. Stem Cell wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is U.S. Stem Cell's next earnings date?

U.S. Stem Cell is scheduled to release its next quarterly earnings announcement on Wednesday, November 25th 2020.
View our earnings forecast for U.S. Stem Cell
.

How were U.S. Stem Cell's earnings last quarter?

U.S. Stem Cell, Inc. (OTCMKTS:USRM) issued its earnings results on Wednesday, August, 7th. The company reported $0.00 earnings per share (EPS) for the quarter. The firm had revenue of $1.30 million for the quarter.
View U.S. Stem Cell's earnings history
.

Who are some of U.S. Stem Cell's key competitors?

What other stocks do shareholders of U.S. Stem Cell own?

Who are U.S. Stem Cell's key executives?

U.S. Stem Cell's management team includes the following people:
  • Mr. Michael Tomas, CEO, Pres, CFO & Director (Age 54, Pay $1.81M)
  • Dr. Colleen Robb, Sr. Compliance Officer
  • Mr. Phil Posa, Sr. VP of U.S. & International Sales
  • Ms. Evelyn Flores, Corp. Controller
  • Dr. Sergio Pinski, Medical Director & Member of Scientific Advisory Board
  • Mr. James L. Greene, Clinical Operations Consultant
  • Fabianne Gershon, Consultant

What is U.S. Stem Cell's stock symbol?

U.S. Stem Cell trades on the OTCMKTS under the ticker symbol "USRM."

How do I buy shares of U.S. Stem Cell?

Shares of USRM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is U.S. Stem Cell's stock price today?

One share of USRM stock can currently be purchased for approximately $0.01.

How big of a company is U.S. Stem Cell?

U.S. Stem Cell has a market capitalization of $2.87 million and generates $6.70 million in revenue each year. U.S. Stem Cell employs 10 workers across the globe.

What is U.S. Stem Cell's official website?

The official website for U.S. Stem Cell is www.us-stemcell.com.

How can I contact U.S. Stem Cell?

U.S. Stem Cell's mailing address is 1560 SAWGRASS CORPORATE PKWY 4TH FLOOR, SUNRISE FL, 33325. The company can be reached via phone at 954-835-1500 or via email at [email protected]

This page was last updated on 11/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.